IRVINE, CA--(Marketwired - Jun 16, 2015) - NuGene International, Inc. ("NuGene") (OTCQB: NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, announced the launch of its skin care therapy Trial/Travel Pack. The new Trial/Travel Pack contains NuGene's top four skin treatment therapies in convenient 10mL sizes.

Universal Cream - Along with working to smooth fine lines and wrinkles, this lightweight topical cream aims to improve aging tone and texture and reduce puffiness and dark circles without heaviness or oiliness. Princeton Consumer Research ("PCR") conducted a company-financed study on NuGene's behalf which concluded that Universal Cream applied site had a 45.6% reduction of fine lines and wrinkles and a 16.3% improvement in the moisture level after eight weeks of treatment.

Universal Serum - NuGene's signature serum restores luminosity by encouraging aging skin to behave more like younger skin, making an improvement in the appearance of wrinkles, fine lines, dark spots and rough texture. PCR also conducted a company-financed study on NuGene's behalf which concluded that the application of the Universal Serum and Eye Serum resulted in a 40.7% reduction of fine lines and wrinkles and a 20.4% improvement in the moisture level after eight weeks of treatment.

Eye Serum - This product is designed to target the eye contour - the area of the face most susceptible to the visible signs of age. NuGene's Eye Serum works to help restore youthful luminosity around the eyes and minimize the appearance of future signs of aging.

Light & Bright Gel - This gel works to reduce the look of dark spots and excess pigmentation while increasing overall radiance. This is accomplished without the harsh ingredients typically found in brightening products.

"These are four of our more popular skin care products," stated Ms. Janine Coppola, Senior Director of Brand Marketing for NuGene. "Many people who use our products see results in only a few weeks and with this starter pack, they can sample the products and see for themselves how invigorating and effective they are. We have had numerous requests for a trial package of popular products and created our starter pack in response to this demand."

About NuGene International, Inc.
NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments." The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has four patents pending covering 15 unique applications and inventions. NuGene's goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 10-Q filed with the Commission on May 15, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.

Contact Information:

Investor/ Media Relations:
Chris Rosgen
Capital Market Relations